… molnupiravir's potential for causing adverse events, 17 this study aimed to evaluate
molnupiravir-related adverse events in COVID-19 … outcome of molnupiravir for treatment of …

… Nirmatrelvir/ritonavir was comparable to molnupiravir in achieving better clinical outcomes
(… study, the use of oral antivirals to treat COVID-19 was associated with a reduced risk of …

… We excluded persons who received any COVID-19 treatment before the test-positive date
… progression to severe COVID-19 (Supplement Tables 2 and 3, available at Annals.org) (19). …

… era of COVID-19, approximately one-tenth of patients experienced symptom recurrence after
treatment with nirmatrelvir-ritonavir or molnupiravir. … the phenomena of COVID-19 rebound. …

… of COVID-19, the risk of progression (death or hospitalization) did not differ among patients
treated with molnupiravir… 2.5% of treated patients died or were hospitalized due to COVID-19. …

… is found to be the first orally acting efficacious drug to treat COVID-19 cases. It was … treating
adults with mild to moderate COVID-19 patients. Considering the importance of molnupiravir, …

… , and niclosamid in the treatment of COVID-19. Finally, the results of phase … molnupiravir,
PF-07321332, PF-07304814, plitidepsin and AT-527 are effective in the treatment of COVID-19…

… ), the effect of molnupiravir in nonhospitalized COVID-19 patients was investigated. This
study aimed to measure the efficacy of molnupiravir in treating COVID-19 based on the …

… of molnupiravir/favipiravir in the treatment of COVID-19 Both … randomly grouped and treated
with vehicle or molnupiravir (b i… tissues Vehicle-treated animals showed detectable virus …

… of COVID-19 … COVID-19 in animal/preclinical investigations and have progressed to
human clinical trials, among which Molnupiravir being authorized for treatment of COVID-19 …